Investigators developed a pooled method for simultaneously sequencing RNA in bulk sets of samples being profiled by high-throughput screening assays.
The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.
A Brown University-led team demonstrated the utility of its "massively parallel splicing assay," or MaPSy, assay by profiling splice effects for thousands of mutations.
Bioké will exclusively distribute Acea's xCelligence cell analyzer in Belgium, the Netherlands, and Luxembourg.
Privately held TransCell specializes in primary cell-based phenotypic screening assays.
The company plans to use the funds to support the worldwide launch of its commercial platform for propagation and gene editing in cell types that are difficult to transfect.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
Analysis of a gene associated with basal progenitor cell expansions in the brain suggests a single splice site change led to human-specific forms of the gene transcript.
Notable is adopting Labcyte's Echo acoustic liquid handling platform to screen cancer patients' tumor cells for response to individual and combination therapies.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.